Kinnevik has made strategic investments totaling SEK 1,015 million in several high-growth tech and biotech companies, showcasing its strong performance and confidence in future market trends.
Information on the Target
Kinnevik, led by CEO Georgi Ganev, has demonstrated a strong performance in 2025, with core companies reporting an average revenue growth of 35 percent and an improvement in EBITDA margins by 2 percentage points year-over-year. The positive trends observed in lead indicators suggest a robust outlook for 2026, indicating the strength of Kinnevik's investment strategy.
In this quarter, Kinnevik invested a total of EUR 15 million in Mews, capitalizing on its successful go-to-market strategy and product development milestones, which have resulted in the company exceeding EUR 330 million in run-rate revenues. Additionally, Kinnevik's strategic participation in various funding rounds showcases its commitment to nurturing innovative companies poised for growth.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The investment landscape in Sweden, where Kinnevik is based, is characterized by a burgeoning tech sector. Companies in various fields including AI, biotechnology, and software development are experiencing significant
Similar Deals
ANTCO Investment Group AB (publ) → NOSIUM AB (publ)
2025
Kinnevik
invested in
Nory
in 2025
in a Other VC deal